Regeneron and Intellia Therapeutics to jointly develop CRISPR/Cas9 for gene editing

12 April 2016

US biotech Regeneron Pharmaceuticals (Nasdaq: REGN) and Intellia Therapeutics have signed a licensing and collaboration agreement to advance CRISPR/Cas 9 gene editing technology.

In addition to the discovery, development and commercialization of new therapies, the companies will focus on technology development of the CRISPR/Cas9 platform.

CRISPR (clustered regularly interspaced short palindromic repeats) is a technology that allows scientists to precisely edit the genes of targeted cells and is considered a powerful tool for creating very specific models of disease for use in drug discovery.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK